TWI783993B - 尼拉帕尼(niraparib)之製備方法 - Google Patents

尼拉帕尼(niraparib)之製備方法 Download PDF

Info

Publication number
TWI783993B
TWI783993B TW107113922A TW107113922A TWI783993B TW I783993 B TWI783993 B TW I783993B TW 107113922 A TW107113922 A TW 107113922A TW 107113922 A TW107113922 A TW 107113922A TW I783993 B TWI783993 B TW I783993B
Authority
TW
Taiwan
Prior art keywords
formula
salt
acid
compound
optionally substituted
Prior art date
Application number
TW107113922A
Other languages
English (en)
Chinese (zh)
Other versions
TW201841889A (zh
Inventor
艾利斯戴爾 詹姆士 史都華
安東尼 約瑟夫 多托
星 陳
光中 吳
Original Assignee
美商提薩羅有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商提薩羅有限公司 filed Critical 美商提薩羅有限公司
Publication of TW201841889A publication Critical patent/TW201841889A/zh
Application granted granted Critical
Publication of TWI783993B publication Critical patent/TWI783993B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C07C303/44—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
TW107113922A 2017-04-24 2018-04-24 尼拉帕尼(niraparib)之製備方法 TWI783993B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762489387P 2017-04-24 2017-04-24
US201762489415P 2017-04-24 2017-04-24
US62/489,387 2017-04-24
US62/489,415 2017-04-24

Publications (2)

Publication Number Publication Date
TW201841889A TW201841889A (zh) 2018-12-01
TWI783993B true TWI783993B (zh) 2022-11-21

Family

ID=63919973

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107113922A TWI783993B (zh) 2017-04-24 2018-04-24 尼拉帕尼(niraparib)之製備方法

Country Status (15)

Country Link
US (2) US11161834B2 (cg-RX-API-DMAC7.html)
EP (1) EP3615513B1 (cg-RX-API-DMAC7.html)
JP (1) JP7179014B2 (cg-RX-API-DMAC7.html)
KR (1) KR102582624B1 (cg-RX-API-DMAC7.html)
CN (2) CN118271233A (cg-RX-API-DMAC7.html)
AU (2) AU2018258274C1 (cg-RX-API-DMAC7.html)
CA (1) CA3060715C (cg-RX-API-DMAC7.html)
ES (1) ES2926255T3 (cg-RX-API-DMAC7.html)
IL (1) IL270068B (cg-RX-API-DMAC7.html)
MA (1) MA48475A (cg-RX-API-DMAC7.html)
MX (1) MX393879B (cg-RX-API-DMAC7.html)
SG (1) SG11201909807TA (cg-RX-API-DMAC7.html)
TW (1) TWI783993B (cg-RX-API-DMAC7.html)
WO (1) WO2018200517A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201906944B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230042136A (ko) 2016-06-29 2023-03-27 테사로, 인코포레이티드 난소암의 치료 방법
TWI761476B (zh) 2017-03-27 2022-04-21 美商提薩羅有限公司 尼拉帕尼(niraparib)組合物
AU2018258274C1 (en) 2017-04-24 2021-12-02 Tesaro, Inc. Methods of manufacturing of niraparib
TWI879716B (zh) 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
AU2018270112A1 (en) 2017-05-18 2019-12-12 Tesaro, Inc. Combination therapies for treating cancer
SG11202002113TA (en) 2017-09-26 2020-04-29 Tesaro Inc Niraparib formulations
CA3076515A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. Combination therapies for treating cancer
CA3076859A1 (en) 2017-10-06 2019-04-11 Tesaro, Inc. Combination therapies and uses thereof
TWI825191B (zh) 2018-10-03 2023-12-11 美商提薩羅有限公司 尼拉帕尼（niraparib）游離鹼之結晶形
CN112300074B (zh) * 2019-08-02 2023-12-29 北京盈科瑞创新药物研究有限公司 一种吲唑甲酰胺类化合物及其制备方法和应用
JP2025508399A (ja) 2022-02-15 2025-03-26 テサロ， インコーポレイテッド 脳がんの処置のためのニラパリブの使用
WO2024142096A1 (en) * 2022-12-29 2024-07-04 Dr. Reddy’S Laboratories Limited Process for preparation of niraparib tosylate and its intermediates
WO2025017711A1 (en) * 2023-07-20 2025-01-23 Natco Pharma Limited An improved process for the preparation of niraparib tosylate monohydrate

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
JP4213771B2 (ja) 1997-04-23 2009-01-21 株式会社カネカ 光学活性アミノ化合物の製造方法
DK2270234T3 (da) 1997-12-08 2013-06-03 California Inst Of Techn Fremgangsmåde til fremstilling af polynukleotid- og polypeptidsekvenser
JP4221100B2 (ja) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 半導体装置
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
EP1272967A2 (en) 2000-03-30 2003-01-08 Maxygen, Inc. In silico cross-over site selection
US6759554B2 (en) 2001-04-24 2004-07-06 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
EP1805164B9 (en) 2004-09-29 2011-09-07 Mitsubishi Tanabe Pharma Corporation 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors
AU2007232297B2 (en) 2006-04-03 2012-09-20 Msd Italia S.R.L. Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors
CA2661605A1 (en) 2006-08-31 2008-03-06 Schering Corporation Hydantoin derivatives useful as antibacterial agents
GEP20115337B (en) 2007-01-10 2011-11-25 St Di Ricerche Di Biologia Molecolare P Angeletti Spa Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
EP2132322A4 (en) 2007-03-02 2013-02-20 Richmond Chemical Corp METHOD FOR INCREASING YIELD AND IMPROVING PURIFICATION OF PRODUCTS FROM REACTIONS WITH TRANSAMINASE
AR065804A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
WO2008132139A2 (en) 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
EP2240466B1 (en) 2008-01-08 2015-07-29 Merck Sharp & Dohme Limited Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
EP2401366B1 (en) 2009-02-26 2013-12-18 Codexis, Inc. Transaminase biocatalysts
JP2010269667A (ja) 2009-05-20 2010-12-02 Alps Electric Co Ltd 多回転角度検出装置
US8932836B2 (en) 2010-08-16 2015-01-13 Codexis, Inc. Biocatalysts and methods for the synthesis of (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine
CA2819400A1 (en) 2010-11-30 2012-06-07 Takeda Pharmaceutical Company Limited Bicyclic compound
EP2673260B1 (en) 2011-02-08 2016-08-17 Pfizer Inc Glucagon receptor modulator
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9073911B2 (en) 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
EP3406594A1 (en) 2012-12-07 2018-11-28 Merck Sharp & Dohme Corp. Biocatalytic transamination process
WO2014088983A1 (en) 2012-12-07 2014-06-12 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
EP3230472A4 (en) 2014-12-08 2018-06-13 Myriad Genetics, Inc. Methods and materials for predicting response to niraparib
KR20230042136A (ko) 2016-06-29 2023-03-27 테사로, 인코포레이티드 난소암의 치료 방법
CN106496187A (zh) * 2016-09-14 2017-03-15 陕西科技大学 一种制备PARP抑制剂Niraparib的合成方法
CN106432055A (zh) * 2016-09-17 2017-02-22 青岛辰达生物科技有限公司 一种尼拉帕布中间体4‑（哌啶‑3‑基）苯胺的制备方法
CN106432057A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 一种制备(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的方法
CN106432056A (zh) * 2016-09-17 2017-02-22 青岛辰达生物科技有限公司 一种尼拉帕布中间体(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的制备方法
TWI761476B (zh) 2017-03-27 2022-04-21 美商提薩羅有限公司 尼拉帕尼(niraparib)組合物
KR20190130625A (ko) 2017-03-27 2019-11-22 테사로, 인코포레이티드 니라파립 제제
AU2018258274C1 (en) 2017-04-24 2021-12-02 Tesaro, Inc. Methods of manufacturing of niraparib
TWI879716B (zh) 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
AU2018270112A1 (en) 2017-05-18 2019-12-12 Tesaro, Inc. Combination therapies for treating cancer
SG11202002113TA (en) 2017-09-26 2020-04-29 Tesaro Inc Niraparib formulations
CA3076515A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. Combination therapies for treating cancer
CA3076859A1 (en) 2017-10-06 2019-04-11 Tesaro, Inc. Combination therapies and uses thereof
WO2019133697A1 (en) 2017-12-27 2019-07-04 Tesaro, Inc. Methods of treating cancer
AU2019215450A1 (en) 2018-02-05 2020-08-27 Tesaro, Inc Pediatric niraparib formulations and pediatric treatment methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Wallace, D. J., Baxter, C. A., Brands, K. J. M., Bremeyer, N., Brewer, S. E., Desmond, R., … Zhou, G. (2011). Development of a Fit-for-Purpose Large-Scale Synthesis of an Oral PARP Inhibitor. Organic Process Research & Development, 15(4), 831–840 Development of a Fit-for-Purpose Large-Scale Synthesis of an Oral PARP Inhibitor. Organic Process Research & Development 15(4) Organic Process Researc *

Also Published As

Publication number Publication date
CA3060715A1 (en) 2018-11-01
EP3615513B1 (en) 2022-07-20
US20220041575A1 (en) 2022-02-10
TW201841889A (zh) 2018-12-01
AU2018258274A1 (en) 2019-11-14
IL270068B (en) 2022-06-01
CN118271233A (zh) 2024-07-02
ES2926255T3 (es) 2022-10-24
US20200055837A1 (en) 2020-02-20
MA48475A (fr) 2020-03-04
KR102582624B1 (ko) 2023-09-22
CA3060715C (en) 2024-10-01
AU2021215116A1 (en) 2021-08-26
NZ758948A (en) 2024-04-26
KR20200021456A (ko) 2020-02-28
WO2018200517A1 (en) 2018-11-01
SG11201909807TA (en) 2019-11-28
US11161834B2 (en) 2021-11-02
EP3615513A1 (en) 2020-03-04
AU2018258274B2 (en) 2021-05-13
JP2020517668A (ja) 2020-06-18
JP7179014B2 (ja) 2022-11-28
BR112019022320A2 (pt) 2020-05-26
AU2018258274C1 (en) 2021-12-02
CN110753684A (zh) 2020-02-04
EP3615513A4 (en) 2020-12-09
US11629137B2 (en) 2023-04-18
AU2021215116B2 (en) 2022-12-01
ZA201906944B (en) 2023-03-29
MX393879B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
TWI783993B (zh) 尼拉帕尼(niraparib)之製備方法
JP4977668B2 (ja) ピラゾロ［１，５−ａ］ピリジン化合物およびその医薬
AU2018326497A1 (en) Spirocycle compounds and methods of making and using same
EP3455226A1 (en) Spirocycle compounds and methods of making and using same
WO2009112524A1 (en) Pyridopyrimidines as plk1 ( polo-like kinase) inhibitors
KR20230058466A (ko) 신규한 rho-연관 단백질 인산화효소 억제제의 제조 방법 및 제조 방법 중의 중간체
US11739088B2 (en) Synthesis of heterocyclic compounds
WO2025096710A1 (en) Modulators of bcl6 as ligand directed degraders
IL319880A (en) TEAD inhibitors and their uses
AU2013369037A1 (en) Process for preparing 7beta-substituted 6alpha,14alpha -ethenomorphinans and 7beta-substituted 6alpha,14alpha-ethanomorphinans
HK40025665A (en) Methods of manufacturing of niraparib
HK40025665B (en) Methods of manufacturing of niraparib
EA044378B1 (ru) Способы изготовления нирапариба
WO2025140532A1 (en) Novel compounds as glp-1r agonists and uses thereof
WO2025140533A1 (en) Novel compounds as glp-1r agonists and uses thereof
HK40085073A (en) Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method
CN117642397A (zh) 经修饰的蛋白质和蛋白质结合剂
BR112019022320B1 (pt) Processo para preparar niraparibe